Evidence map›Paper›PMID 40830877›Full record

ArticleChinese medicine2025

Identification of anti-fibrotic compounds from Piper longum L via hollow fiber cell fishing and high-performance liquid chromatography with in vivo and in vitro validation.

Jie Tian, Nan Zhou, Heng Wang, Wanghui Jing, Guoping Zheng

Abstract read
In one paragraph

Article in Chinese medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jie TianDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Shanxi Medical University, Taiyuan, Shanxi, China.
Nan ZhouDepartment of Biochemistry and Molecular Biology, School of Basic Medical Science, Shanxi Medical University, Taiyuan, Shanxi, China.
Heng WangCentre for Transplant and Renal Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia.
Wanghui Jing *Shaanxi Engineering Research Center of Cardiovascular Drugs Screening & Analysis, Xi'an, Shanxi, China. jingwanghui1987@163.com.ORCID http://orcid.org/0000-0001-9594-2989
Guoping Zheng *Department of Biochemistry and Molecular Biology, School of Basic Medical Science, Shanxi Medical University, Taiyuan, Shanxi, China. guoping.zheng@sydney.edu.au.

Funding

the National Natural Scientific Foundation of China 82174059the Youth Program of the Shanxi Provincial Health Commission 2023121
6 · The paper itself

Abstract

backgroundTraditional Chinese medicine (TCM) is an important source of bioactive compounds, hence enjoying a wide application in clinical treatment, while its pharmacodynamic material basis remains difficult to elucidate as it has a complex chemical composition. Piper longum L is a commonly used herbal medicine in prescriptions for chronic kidney disease (CKD), yet its key active ingredients responsible for anti-renal fibrosis effects remain unclear. This study aimed to establish a novel and efficient strategy for the screening and identification of anti-fibrotic compounds from Piper longum L.

methodsHK-2 cells with fibrotic features induced by transforming growth factor-β (TGF-β) were used to develop a hollow fiber cell fishing coupled with high-performance liquid chromatography (HFCF-HPLC) mode. This model was integrated with network pharmacology and molecular biology techniques to screen and validate active anti-fibrotic compounds in Piper longum L. The in vivo efficacy of the identified compounds was further evaluated by a unilateral ischemia-reperfusion injury (uIRI) model with delayed contralateral nephrectomy in C57BL/6 J mice. Serum creatinine (SCr) and blood urea nitrogen (BUN) levels were taken into account to assess the renal function, while immunohistochemistry and western blot served for analyzing the fibrosis markers α-SMA and collagen-I.

resultsHFCF-HPLC screening identified two key active compounds from Piper longum L: piperlongumine (PIPA) and piperlonguminine (PLG). Among them, PIPA exhibited the strongest inhibitory effect on the expression of fibrosis markers in vitro. In vivo studies demonstrated that PIPA significantly reduced renal fibrosis in the uIRI model, as indicated by lower SCr and BUN levels, improved renal histopathology, and reduced extracellular matrix deposition.

conclusionsA novel HFCF-HPLC model was successfully established to screen active compounds from TCM against renal fibrosis. PIPA was identified as a promising anti-fibrotic agent from Piper longum L, demonstrating significant renoprotective effects in in vitro and in vivo models. This work advances the modernization of herbal medicine research by offering a integrated strategy for identifying bioactive TCM components.

Indexed as

Activity screeningA hollow fiber cell fishingHPLCPiper longum LRenal fibrosis

Identifiers

PMID40830877
PMCPMC12362919

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.